Key result
Systemic therapy yields ~20-month survival in a rare case of primary cardiac leiomyosarcoma.
Why the study?
Primary cardiac leiomyosarcoma is an extremely rare and aggressive sarcoma with challenging diagnosis and nonstandardized treatment, resulting in poor prognosis.
Case Report (n=1)
This case highlights the importance of timely multimodal imaging for diagnosing rare primary cardiac leiomyosarcoma and documents a longer survival than typically seen.
Cautions against generalizing single-case outcomes in rare cardiac sarcomas; extends sparse evidence on systemic therapy approaches.
BACKGROUND: Primary cardiac leiomyosarcoma is an extremely rare and aggressive sarcoma. Its diagnosis is challenging, and its treatment is not yet standardized, resulting in a poor prognosis. CASE SUMMARY: A 29-year-old man presented with a 1-month history of respiratory symptoms, initially treated with antiflu medication and antibiotics, showing no clinical improvement. During cardiology consultation, a cardiac mass was identified on echocardiography and subsequently characterized by cardiac magnetic resonance and positron emission tomography. Histopathological and immunohistochemical studies confirmed the diagnosis. The patient remains alive at 20 months while receiving systemic treatment. DISCUSSION: The diagnosis of primary cardiac leiomyosarcoma is challenging due to its rarity and aggressive behavior; it requires multimodal imaging and immunohistochemical confirmation. Its treatment remains nonstandardized, with limited evidence supporting the benefit of combining surgery, chemotherapy, and/or radiotherapy. This case highlights the importance of timely diagnosis and documents longer survival than typically reported.
No takes yet. Share an insight, caveat, or question.
Calzadilla-Gutiérrez et al. (2026) conducted a case report in Primary cardiac leiomyosarcoma (n=1). Systemic treatment was evaluated on Survival. Systemic treatment of a 29-year-old man with primary cardiac leiomyosarcoma resulted in an ongoing survival of 20 months, which is longer than typically reported for this aggressive tumor.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: